View our Xtalks presentation with the Award winning ICON and STUDIUS, two new platforms for the therapeutic antibody production community
Smarter workflows for future medicines
For over a decade, Solentim has enabled workflows, validated through Regulatory submission, in key cell therapy areas including cell line development, vaccines stem cells and gene therapy.
Introducing the data generators:
VIPS™, Cell Metric® and ICON™
Explore our range of technologies for seeding, assurance and productivity measurements. Learn how our industry accepted instruments are the backbone to cell therapy development workflows.
Reagents for enhanced seeding and accelerated cell growth
Featuring MatriClone™ our imaging ready seeding matrix for iPSC cells and InstiGRO™, our powerful growth supplement for CHO and HEK cells.
Introducing STUDIUS™: The new standard for cell line development
An over-arching data management system working with Solentim platforms to drive smart decision and keener workflows.
"A New Platform for Clinical Gene Editing of iPSCs to Make Clonal Cell Banks"
Solentim agrees exclusive distribution deal with Matrixome to supply clinical manufacturing grade laminin to cell therapy market
Bournemouth, UK, 10th June 2021 / Solentim, the trusted global leader for solutions to create, isolate, and characterize the highest value cells for the development of new biological medicines, has today announced an exclusive distribution agreement with Matrixome Inc. (Japan) for use in conjunction with Solentim’s instrumentation. Under the new agreement, Solentim will add a clinical manufacturing-grade …
Enjoy a new 15 minute virtual demonstration from within Solentim’s laboratories and download resources to learn how our new workflow for iPSC seeding can help you overcome challenges associated with iPSC workflows. iPSCs have practically an unlimited proliferation potential, and a capability to differentiate into any cell type in the human body. Because of this, …
Solentim, the trusted global leader for solutions to create, isolate, and characterize the highest value cells for the development of new biological medicines, is delighted to announce that it will be presenting and exhibiting at the ISSCR 2021 Annual Meeting, taking place virtually, 21-26 June 2021. Dr Ian Taylor, Chief Business Officer, Solentim will present …